Please login to the form below
Akorn Pharma
This page shows the latest Akorn Pharma news and features for those working in and with pharma, biotech and healthcare.
Fresenius says Akorn investigation could affect takeover
External ‘experts’ are investigating alleged breaches of data integrity requirements. Fresenius Kabi says its $4.3bn deal to acquire US generic drugmaker Akorn Pharma could be scuppered by an FDA probe ... period of 2016, with the declines all coming
Latest news
-
Fresenius Kabi buys Akorn and Merck's biosimilar businesses
Fresenius is paying $34 per share for Akorn - valuing the company at $4.3bn - and will also assume around $450m in debt held by the US firm. ... Rumours of a deal have been circulating for several weeks, and Akorn confirmed it was in negotiations with
More from news
Approximately 1 fully matching, plus 1 partially matching documents found.
Featured jobs
- Global Business Development Director – Health Education
-
excellent commission
-
Account Director, Medical Education
-
Salary TBC
- Senior Account Director development role to Business Director, H...
-
Excellent package
- Editorial Assistant Medical Education Agency
-
£25, 000 - £26, 000
- Technical Manager – Developer and Commercial Excellence, Healthc...
-
Excellent package
-
Business Director
-
Competitive Salary Offered
- Account Manager / Senior Account Manager
-
35, 000-40, 000
-
Associate Director
-
£75, 000-90, 000
-
Medical Writer
-
Salary TBC
-
Senior Account Manager
-
Competitive Salary Offered
- Senior Account Manager, Rare Diseases – Medical Communications, ...
-
Excellent package
-
Account Manager / Account Director
-
Competative
-
Senior Medical Writer
-
Salary TBC
- Engagement Expert, Healthcare Brand Communications, London
-
Excellent package
-
Account Director
-
Competitive Salary Offered
Subscribe to our email news alerts
- Pfizer takeover rumour ignites Amarin shares
- Welcome to the Communique Awards - Communiqué Awards 2018
- NICE rejects Novartis migraine treatment Aimovig
- AstraZeneca unveils reorg, hires controversial José Baselga as cancer chief
- GSK upbeat on its return to oncology market
- BMS and Celgene deal sparks debate on pharma profit motive, more M&A
- The new UK government-pharma industry pricing agreement – welcome news, but there are lessons to be learnt
- The UK’s new five-year pricing agreement
- Lucid kick-starts 2019 with spellbinding new additions to its writing and account teams
- New hires at Nanoform, Leo Pharma and Calliditas
- Page & Page welcomes Clare Bates to the team
- Lucid Group prepare for a transformative year with the appointment of a new Director of Corporate Development
PMHub
Star
We're passionate about helping our clients to make a real commercial impact. We achieve this through our unique approach to...
Latest intelligence
- The new UK government-pharma industry pricing agreement – welcome news, but there are lessons to be learnt
- ...
- The UK’s new five-year pricing agreement
- Pharma has agreed to capped growth again – in exchange for uptake promises...
- Digital applications are transforming the market access landscape
- Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
Quick links
Infographics
